COR Earnings Prediction
The chart below shows how COR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, COR sees a -2.65% change in stock price 10 days leading up to the earnings, and a +0.01% change 10 days following the report. On the earnings day itself, the stock moves by +1.53%. This data can give you a slight idea of what to expect for the next quarter's release.
COR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
79.05B
14.69%
6.48%
Gross Margin
2.74%
-2.49%
-2.84%
Operating Margin
0.85%
8.97%
-10.53%
Net Margin
0.01%
-98.04%
-98.48%
EPS
0.02
-98.84%
-99.17%
No Data Available
COR Earnings Analysis
Cencora, Inc. Corporation (COR.N) Earnings Conference Call
Positive
Earnings Increase Announcement: Cencora reported a 15% increase in adjusted earnings for fiscal year 2024, reaching $13.76 per share compared to the previous year.
Revenue Growth Overview: Consolidated revenue for Cencora was $294 billion, reflecting a 12% growth driven by a 13% increase in the U.S. Health Care Solutions segment.
Operating Income Increase: The company achieved a consolidated operating income of $3.6 billion, marking an 11% increase due to growth in both U.S. and International Health Care Solutions segments.
Strong Free Cash Flow: Cencora generated $3.1 billion in adjusted free cash flow for the fiscal year 2024, ending the year with a cash balance of $3.1 billion, exceeding expectations.
Dividend Increase Announcement: The Board of Directors approved an 8% increase in the quarterly dividend, marking the 20th consecutive annual dividend increase.
Negative
Gross Profit Margin Decline: Consolidated gross profit margin was 3.1%, a decrease of 24 basis points compared to the prior year quarter due to higher growth in our US Health Care Solutions segment, which has lower gross profit margin than our International Health Care Solutions segment.
Operating Expenses Increase: Consolidated operating expenses were $1.6 billion, up 7% as a result of higher distribution, selling and administrative expenses in the quarter to support our revenue growth.
Operating Income Increase: Consolidated operating income was $851 million, up 6% compared to the prior year quarter, with the increase driven by strong growth in the US Health Care Solutions segment, partially offset by a decline in the International Health Care Solutions segment.
Net Interest Expense Reduction: Net interest expense was $21 million, a decrease of 66%, driven by strong free cash flow, enabling an increase in interest income as a result of higher investment rates and investment cash balances in the quarter.
Effective Tax Rate Decline: The effective tax rate in the fourth quarter was 20.3% compared to 21.6% in the prior year quarter, bringing our fully year 2024 effective tax rate down to 20.8%.
COR FAQs
How does COR typically perform around its earnings report dates?
Is Cencora, Inc. (COR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
COR Earning Call Sentiment
Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript
1.0x
00:00
00:00
COR.N
2.58%Positive
The earnings call reveals strong financial metrics with a 15% increase in EPS and revenue, but concerns about goodwill impairment, supply chain challenges, and potential customer loss weigh on sentiment. The 8% dividend increase and share repurchases are positive, but broader market demand challenges and unclear guidance on regulatory impacts temper enthusiasm. The Q&A section highlights management's confidence but lacks detailed guidance, especially regarding IRA changes. Overall, the mixed signals suggest a neutral stock price movement over the next two weeks.